Login / Signup

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.

Stephen H RappaportJenna M ClarkSamantha DelibertKaylee M MaynardParitosh PrasadDavid C KaufmanAnthony P PietropaoliCaroline M QuillChristine M Groth
Published in: American journal of respiratory and critical care medicine (2020)
Keyphrases
  • coronavirus disease
  • sars cov
  • venous thromboembolism
  • direct oral anticoagulants
  • atrial fibrillation